Literature DB >> 1935820

The prolactin/growth hormone receptor family.

P A Kelly1, J Djiane, M C Postel-Vinay, M Edery.   

Abstract

PRL and GH are hormones with a wide spectrum of actions. Specific receptors are widely distributed in a number of classical target organs, but other tissues that are not known targets also contain measurable binding sites or receptor mRNA. The most likely explanation is that PRL and GH cause effects that have not yet been characterized in certain tissues. Cloning of the cDNAs encoding PRL and GH receptors has led to the discovery that the receptors, like the hormones themselves, form a gene family. Multiple receptor forms have been identified, including a short form, which for PRL is a membrane-bound receptor or for GH is a soluble BP, and a long form, which for both PRL and GH is a membrane-bound receptor. PRL and GH receptors, and the mRNAs encoding them, can be up- and down-regulated. GH induces an up-regulation of both GH and PRL receptors, whereas PRL stimulates an increase of only its own receptor. High concentrations of either hormone induce a homologous down-regulation of receptor expression. An assay has been developed to measure the functional activity of different forms of PRL receptor by cotransfecting a milk protein fusion gene specific to PRL coupled to a reporter-gene along with the cDNA of the PRL receptor. Although the short form represents the major form present in rat mammary gland, only the long form of receptor is able to stimulate milk protein gene transcription. For GH, increased expression of the receptor in some target cells is accompanied by a modest enhancement of the response to GH. No single second messenger mediating the action of either PRL or GH has been identified. Several potential components of the signal transduction pathways have been identified, but as yet none has clearly been shown to be able to mimic the effect of PRL or GH. Because of the wide range of biological actions associated with PRL, and the existence of various forms of PRL receptors, it is doubtful that one unifying mechanism of action will be found for this hormone. No human or animal model of a genetic defect of the PRL receptor has thus far been published. Mutations in the GH receptor gene have been demonstrated in Laron type dwarfism. Different exon deletions or point or nonsense mutations resulting in modifications in the extracellular, GH binding region of the GH receptor have been reported.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1935820     DOI: 10.1210/edrv-12-3-235

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  82 in total

Review 1.  Mammary gland development in prolactin receptor knockout mice.

Authors:  C J Ormandy; N Binart; P A Kelly
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

Review 2.  Recombinant analogues of prolactin, growth hormone, and placental lactogen: correlations between physical structure, binding characteristics, and activity.

Authors:  A Gertler
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

3.  Differential action of two prolactin isoforms on ischemia and re-perfusion-induced arrhythmias in rats in vivo.

Authors:  T F Krzeminski; K Mitrega; M Porc; M Zorniak; F Ryszka; Z Ostrowska; B Kos-Kudła
Journal:  J Endocrinol Invest       Date:  2010-10-04       Impact factor: 4.256

4.  Human growth hormone fragment (hGH44-91) produces insulin resistance and hyperinsulinemia but is less potent than 22 kDa hGH in the rat.

Authors:  M Hettiarachchi; A Watkinson; K C Leung; Y N Sinha; K K Ho; E W Kraegen
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

5.  Sex-dependent roles of prolactin and prolactin receptor in postoperative pain and hyperalgesia in mice.

Authors:  M J Patil; D P Green; M A Henry; A N Akopian
Journal:  Neuroscience       Date:  2013-08-29       Impact factor: 3.590

Review 6.  Human growth hormone doping in sport.

Authors:  M Saugy; N Robinson; C Saudan; N Baume; L Avois; P Mangin
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

7.  The growth hormone receptor interacts with its sheddase, the tumour necrosis factor-alpha-converting enzyme (TACE).

Authors:  Julia A Schantl; Marcel Roza; Peter Van Kerkhof; Ger J Strous
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

8.  Interleukin 2 activates STAT5 transcription factor (mammary gland factor) and specific gene expression in T lymphocytes.

Authors:  K C Gilmour; R Pine; N C Reich
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

9.  Proteasomes mediate prolactin-induced receptor down-regulation and fragment generation in breast cancer cells.

Authors:  Juu-Chin Lu; Timothy M Piazza; Linda A Schuler
Journal:  J Biol Chem       Date:  2005-08-15       Impact factor: 5.157

10.  Inhibition of gonadotropin hormone-releasing hormone release by prolactin from GT1 neuronal cell lines through prolactin receptors.

Authors:  L Milenković; G D'Angelo; P A Kelly; R I Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.